Therapeutics › Metabolic and Endocrine Agents › Insulin Sensitizing Agents · Lifestyle and Environment › Nutrition and Metabolic Health › Blood Sugar and Insulin
PMID 23764390 23764390 DOI 10.1016/j.biochi.2013.05.011 10.1016/j.biochi.2013.05.011 Croze et al. 2013, Croze 2013
Keywords
1-d-myo-inositol-phosphate synthase, 5′ AMP-activated protein kinase, AC, ACC, AGEs, AMP, AMPK, AUC, BMI, Body Mass Index, CDP-DAG, D-chiro-inositol, DCI, Diabetes, Diabetic neuropathy, ECM, FA, FSH, G3PAT, GFR, GK, GLUT-4, GMD, GPI, GS, GSK3, Goto Kakizaki (rat), H(+)/myo-inositol transporter, HDL, HK, HMIT, HOMA-IR, IMPase, INS-2, IPG, IPs, IR, IRS, Inositol, Insulin resistance, LD50, LDL, LH, LysoPI, MI, MIOX, MIPS, MNCV, MetS, Metabolic syndrome, OGTT, PCOS, PDH, PDHP, PDK, PI, PI3K, PIPs, PKA, PKB, PKC, PLC, PLD, PP-InsPs, PP2Cα, Polycystic ovary syndrome, Protein Kinase B, RCT, SHBG, SHR, SMIT1/2, STZ, Sex Hormon Binding Globulin, acetyl-coenzyme A carboxylase, adenosine monophosphate, adenylyl cyclase, advanced glycation end products, area under the curve, cAMP, cyclic AMP, cyclic AMP-dependent protein kinase, cytidine diphosphate-diacylglycerol, extracellular matrix, folic acid, follicle-stimulating hormone, gestational diabetes mellitus, glomerular filtration rate, glucose transporter 4, glycerol-3-phosphate acyltransferase, glycogen synthase, glycogen synthase kinase 3, glycosyl phosphatidylinositol, hexokinase, high density lipoprotein, homeostasis model assessment of insulin resistance, inositol monophosphatase, inositol phosphates (including in particular: Ins-P: inositol monophosphate, IP3, inositol triphosphates, IP6, inositol hexakisphosphates or phytic acid), inositol phosphoglycan, insulin receptor, insulin receptor substrate(s), insulin second messenger with a 4-O-(2-amino-2-deoxy-beta-d-galactopyranosyl)-3-O-methyl-d-chiro-inositol structure, low density lipoprotein, luteinizing hormone, lysophosphatidylinositol, mTOR, mammalian target of rapamycin, median lethal dose, metabolic syndrome, motor nerve conduction velocity, myo-inositol, myo-inositol oxygenase, oral glucose tolerance test, phosphatidylinositol, phosphatidylinositol phosphate lipids (including PIP(2), phosphatidylinositol 4,5-bisphosphate and PIP(3), phosphatidylinositol (3,4,5)-trisphosphate), phosphatidylinositol-3-kinase(s), phosphoinositide-dependent kinase, phospholipase C, phospholipase D, phosphoprotein phosphatase 2C alpha, polycystic ovary syndrome, protein kinase C, pyrophosphate forms of inositol phosphates, pyruvate dehydrogenase, pyruvate dehydrogenase phosphatase, randomized controlled trial, sodium-dependant myo-inositol transporter 1/2, spontaneously hypertensive rat, streptozotocin
